Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telavancin versus standard intravenous therapy for Staphylococcus aureus bacteremia including infective endocarditis
2014-004372-27Phase 3Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Dec 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of telavancin in Staphylococcal bacteremia and endocarditis (IE) (2 arms), sponsored by Theravance Biopharma, Inc. Started Dec 2015; status: completed.
02
Drugs
telavancin
03
Conditions
Staphylococcal bacteremiaendocarditis (IE)
Beyond the preview
Go deeper on 2014-004372-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004372-27.